BioXell Announces Positive Phase IIb Results For Elocalcitol In Benign Prostatic Hyperplasia

BioXell S.p.A. (SWX: BXLN) announced top-line results of its Phase IIb trial of Elocalcitol in Benign Prostatic Hyperplasia (BPH), a common condition among the aging male population. The primary endpoint was met with a high degree of statistical significance, with Elocalcitol effectively arresting prostate growth. Elocalcitol also showed relevant effects on the symptomatic parameters urgency, frequency and nocturia, as well as on the urodynamic parameter maximum urinary flow rate (Qmax). [click link for full article]

More: continued here

Filed under: Men's health on October 20th, 2007